<DOC>
	<DOCNO>NCT01986218</DOCNO>
	<brief_summary>The primary purpose study evaluate safety effectiveness daily dose BMS-986115 subject advance solid tumor</brief_summary>
	<brief_title>Phase I Ascending Multiple-Dose Study BMS-986115 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Subjects histologically cytologically confirm diagnosis solid tumor , advance metastatic , refractory relapse standard therapy know effective treatment Life expectancy least 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status score 01 Prior anticancer treatment permit ( i.e. , chemotherapy , radiotherapy , hormonal , immunotherapy ) At least 4 week must elapse last dose prior anticancer therapy initiation study therapy Subjects know suspect brain metastasis , primary brain tumor , brain site disease Evidence uncontrolled , active infection , require systemic antibacterial , antiviral antifungal therapy ≤ 7 day prior administration study medication Current recent ( within 3 month study drug administration ) gastrointestinal disease chronic intermittent diarrhea , disorder increase risk diarrhea , inflammatory bowel disease . Nonchronic condition ( e.g . infectious diarrhea ) completely resolve least 2 week prior start study treatment exclusionary Any major surgery gastrointestinal disease would interfere administration oral medication Conditions require chronic systemic glucocorticoid use , autoimmune disease severe asthma , exclude inhalation steroid maintenance . Uncontrolled significant cardiovascular disease History medically significant thromboembolic event bleed diathesis within past 6 month Inadequate bone marrow function ( Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 ; Platelet count &lt; 100,000 cells/mm3 ; Hemoglobin &lt; 9.0 g/dL ) Inadequate hepatic function ( Total bilirubin &gt; 1.5 time institutional upper limit normal ( ULN ) ( except know Gilbert 's syndrome ) ; Alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; 2.5 time institutional ULN . ALT AST 3 time institutional ULN permit total bilirubin normal Uncontrolled ( ≥ Grade 2 ) hypertriglyceridemia ( fast triglyceride &gt; 300 mg/dL ( 3.42 mmol/L ) ) Inadequate renal function ( Blood creatinine &gt; 1.5 time institutional ULN ) Positive blood screen hepatitis C antibody , hepatitis B surface antigen , Human Immunodeficiency Virus ( HIV ) 1 , 2 antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>